Importer of Controlled Substances Application: Stepan Company, 41054-41055 [2017-18313]

Download as PDF 41054 Federal Register / Vol. 82, No. 166 / Tuesday, August 29, 2017 / Notices Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. ADDRESSES: DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Cody Laboratories, Inc. ACTION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, SUPPLEMENTARY INFORMATION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before October 30, 2017. DATES: importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on June 12, 2017, Cody Laboratories, Inc., Steve Hartman, VP Compliance, 601 Yellowstone Avenue, Cody, Wyoming 82414 applied to be registered as a bulk manufacturer the following basic classes of controlled substances: Controlled substance Drug code Dihydromorphine ............................................................................................................................................................. Amphetamine ................................................................................................................................................................... Methamphetamine ........................................................................................................................................................... Lisdexamfetamine ............................................................................................................................................................ Methylphenidate .............................................................................................................................................................. Amobarbital ...................................................................................................................................................................... Pentobarbital .................................................................................................................................................................... Secobarbital ..................................................................................................................................................................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... Cocaine ............................................................................................................................................................................ Codeine ........................................................................................................................................................................... Dihydrocodeine ................................................................................................................................................................ Oxycodone ....................................................................................................................................................................... Hydromorphone ............................................................................................................................................................... Diphenoxylate .................................................................................................................................................................. Ecgonine .......................................................................................................................................................................... Hydrocodone ................................................................................................................................................................... Meperidine ....................................................................................................................................................................... Methadone ....................................................................................................................................................................... Methadone intermediate .................................................................................................................................................. Morphine .......................................................................................................................................................................... Thebaine .......................................................................................................................................................................... Oxymorphone .................................................................................................................................................................. Alfentanil .......................................................................................................................................................................... Remifentanil ..................................................................................................................................................................... Sufentanil ......................................................................................................................................................................... Tapentadol ....................................................................................................................................................................... Fentanyl ........................................................................................................................................................................... The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Dated: August 21, 2017. Demetra Ashley, Acting Assistant Administrator. [FR Doc. 2017–18316 Filed 8–28–17; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before September 28, 2017. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before September 28, 2017. DATES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, sradovich on DSK3GMQ082PROD with NOTICES ADDRESSES: Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Stepan Company ACTION: Notice of application. VerDate Sep<11>2014 18:45 Aug 28, 2017 Jkt 241001 PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 9145 1100 1105 1205 1724 2125 2270 2315 8333 9041 9050 9120 9143 9150 9170 9180 9193 9230 9250 9254 9300 9333 9652 9737 9739 9740 9780 9801 Schedule I II II II II II II II II II II II II II II II II II II II II II II II II II II II Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. Comments and requests for hearing on applications to import narcotic raw material are not appropriate. 72 FR 3417 (January 25, 2007). The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with SUPPLEMENTARY INFORMATION: E:\FR\FM\29AUN1.SGM 29AUN1 41055 Federal Register / Vol. 82, No. 166 / Tuesday, August 29, 2017 / Notices respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on January 18, 2017, Stepan Company, Natural Products Dept., 100 W. Hunter Avenue, Maywood, New Jersey 07607 applied to be registered as an importer of coca leaves (9040), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance in bulk for the manufacture of controlled substance for distribution to its customers. Dated: August 21, 2017. Demetra Ashley, Acting Assistant Administrator. [FR Doc. 2017–18313 Filed 8–28–17; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Cambrex Charles City ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before September 28, 2017. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before September 28, 2017. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and DATES: (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. Comments and request for hearing on applications to import narcotic raw material are not appropriate. 72 FR 3417 (January 25, 2007). SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Office of Diversion Control (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on June 12, 2017, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616 applied to be registered as an importer of the following basic classes of controlled substances: Controlled substance Drug code 4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... Phenylacetone ................................................................................................................................................................. Coca Leaves .................................................................................................................................................................... Opium, raw ...................................................................................................................................................................... Poppy Straw Concentrate ............................................................................................................................................... The company plans to import the listed controlled substances for internal use, and to manufacture bulk intermediates for sale to its customers. Dated: August 21, 2017. Demetra Ashley, Acting Assistant Administrator. [FR Doc. 2017–18314 Filed 8–28–17; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE sradovich on DSK3GMQ082PROD with NOTICES Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Noramco, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and DATES: VerDate Sep<11>2014 18:45 Aug 28, 2017 Jkt 241001 applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before October 30, 2017. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 8333 8501 9040 9600 9670 Schedule II II II II II substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on July 6, 2017, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801–4417 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: Controlled substance Marihuana ..................... Tetrahydrocannabinols Codeine-N-oxide ........... Dihydromorphine .......... Hydromorphinol ............ E:\FR\FM\29AUN1.SGM 29AUN1 Drug code 7360 7370 9053 9145 9301 Schedule I I I I I

Agencies

[Federal Register Volume 82, Number 166 (Tuesday, August 29, 2017)]
[Notices]
[Pages 41054-41055]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18313]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Stepan Company

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.34(a) on or before September 28, 2017. Such persons may also file 
a written request for a hearing on the application pursuant to 21 CFR 
1301.43 on or before September 28, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
request for hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, 
Springfield, Virginia 22152. Comments and requests for hearing on 
applications to import narcotic raw material are not appropriate. 72 FR 
3417 (January 25, 2007).

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with

[[Page 41055]]

respect to the promulgation and implementation of 21 CFR part 1301, 
incident to the registration of manufacturers, distributors, 
dispensers, importers, and exporters of controlled substances (other 
than final orders in connection with suspension, denial, or revocation 
of registration) has been redelegated to the Assistant Administrator of 
the DEA Diversion Control Division (``Assistant Administrator'') 
pursuant to section 7 of 28 CFR part 0, appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on 
January 18, 2017, Stepan Company, Natural Products Dept., 100 W. Hunter 
Avenue, Maywood, New Jersey 07607 applied to be registered as an 
importer of coca leaves (9040), a basic class of controlled substance 
listed in schedule II.
    The company plans to import the listed controlled substance in bulk 
for the manufacture of controlled substance for distribution to its 
customers.

    Dated: August 21, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-18313 Filed 8-28-17; 8:45 am]
 BILLING CODE 4410-09-P